Application 761369
- Type
- BLA
- Sponsor
- PFIZER INC
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761369 | Hympavzi | marstacimab-hncq | 351(a) | Rx | 2026-09-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | HYMPAVZI | MARSTACIMAB-HNCQ | INJECTABLE;SUBCUTANEOUS | 300MG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| HYMPAVZI | MARSTACIMAB-HNCQ | Pfizer Laboratories Div Pfizer Inc | a2cc631e-13a6-40c2-acf9-065ccedfb90a | 2026-06-22 | Warnings, Adverse reactions | BLA761369 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.